In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies

Hanne Kinnunen Bown, Catherine Bonn, Stefan T. Yohe, Daniela Bumbaca Yadav, Thomas W. Patapoff, Ann L. Daugherty, Randall J. Mrsny

Research output: Contribution to journalArticle

3 Citations (Scopus)
21 Downloads (Pure)

Abstract

Monoclonal antibodies (mAbs), which are now more frequently administered by subcutaneous (SC) injection rather than intravenously, have become a tremendously successful drug format across a wide range of therapeutic areas. Preclinical evaluations of mAbs to be administered by SC injection are typically performed in species such as mice, rats, minipigs, and cynomolgus monkeys to obtain critical information regarding formulation performance and prediction of PK/PD outcomes needed to select clinical doses for first-in-human studies. Despite extensive efforts, no preclinical model has been identified to date that accurately predicts clinical outcomes for these SC injections. We have addressed this deficiency with a novel in vitro instrument, termed Scissor, to model events occurring at the SC injection site and now further validated this approach using a set of eight mAbs for which clinical PK/PD outcomes have been obtained. Diffusion of these mAbs from the Scissor system injection cartridge into a large volume physiological buffer, used to emulate mAb movement from the SC injection site into the systemic circulation, provided distinct profiles when monitored over a 6 h period. Curve-fitting analysis of these profiles using the Hill equation identified parameters that were used, along with physicochemical properties for each mAb, in a partial least squares analysis to define a relationship between molecule and formulation properties with clinical PK outcomes. The results demonstrate that parameters of protein charge at neutral pH and isoelectric point (pI) along with combined formulation properties such as viscosity and mAb concentration can dictate the movement of the mAb from the injection cartridge to infinite sink compartment. Examination of profile characteristics of this movement provided a strong predictive correlation for these eight mAbs. Together, this approach demonstrates the feasibility of this in vitro modelling strategy as a tool to identify drug and formulation properties that can define the performance of SC injected medicines and provide the potential for predicting clinical outcomes that could be useful for formulation selection and a first-in-human clinical dosing strategy.
Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalJournal of Controlled Release
Volume273
Early online date6 Feb 2018
DOIs
Publication statusPublished - 10 Mar 2018

Fingerprint

Subcutaneous Injections
Biological Availability
Monoclonal Antibodies
Miniature Swine
Drug Compounding
Injections
Macaca fascicularis
Isoelectric Point
Least-Squares Analysis
Viscosity
Buffers
In Vitro Techniques
Pharmaceutical Preparations
Proteins

Keywords

  • Formulation design
  • Monoclonal antibody
  • Subcutaneous injection
  • in vitro model

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies. / Bown, Hanne Kinnunen; Bonn, Catherine; Yohe, Stefan T.; Yadav, Daniela Bumbaca; Patapoff, Thomas W.; Daugherty, Ann L.; Mrsny, Randall J.

In: Journal of Controlled Release, Vol. 273, 10.03.2018, p. 13-20.

Research output: Contribution to journalArticle

Bown, Hanne Kinnunen ; Bonn, Catherine ; Yohe, Stefan T. ; Yadav, Daniela Bumbaca ; Patapoff, Thomas W. ; Daugherty, Ann L. ; Mrsny, Randall J. / In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies. In: Journal of Controlled Release. 2018 ; Vol. 273. pp. 13-20.
@article{49b62331c35b4b6eae93f9fbc19c0952,
title = "In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies",
abstract = "Monoclonal antibodies (mAbs), which are now more frequently administered by subcutaneous (SC) injection rather than intravenously, have become a tremendously successful drug format across a wide range of therapeutic areas. Preclinical evaluations of mAbs to be administered by SC injection are typically performed in species such as mice, rats, minipigs, and cynomolgus monkeys to obtain critical information regarding formulation performance and prediction of PK/PD outcomes needed to select clinical doses for first-in-human studies. Despite extensive efforts, no preclinical model has been identified to date that accurately predicts clinical outcomes for these SC injections. We have addressed this deficiency with a novel in vitro instrument, termed Scissor, to model events occurring at the SC injection site and now further validated this approach using a set of eight mAbs for which clinical PK/PD outcomes have been obtained. Diffusion of these mAbs from the Scissor system injection cartridge into a large volume physiological buffer, used to emulate mAb movement from the SC injection site into the systemic circulation, provided distinct profiles when monitored over a 6 h period. Curve-fitting analysis of these profiles using the Hill equation identified parameters that were used, along with physicochemical properties for each mAb, in a partial least squares analysis to define a relationship between molecule and formulation properties with clinical PK outcomes. The results demonstrate that parameters of protein charge at neutral pH and isoelectric point (pI) along with combined formulation properties such as viscosity and mAb concentration can dictate the movement of the mAb from the injection cartridge to infinite sink compartment. Examination of profile characteristics of this movement provided a strong predictive correlation for these eight mAbs. Together, this approach demonstrates the feasibility of this in vitro modelling strategy as a tool to identify drug and formulation properties that can define the performance of SC injected medicines and provide the potential for predicting clinical outcomes that could be useful for formulation selection and a first-in-human clinical dosing strategy.",
keywords = "Formulation design, Monoclonal antibody, Subcutaneous injection, in vitro model",
author = "Bown, {Hanne Kinnunen} and Catherine Bonn and Yohe, {Stefan T.} and Yadav, {Daniela Bumbaca} and Patapoff, {Thomas W.} and Daugherty, {Ann L.} and Mrsny, {Randall J.}",
year = "2018",
month = "3",
day = "10",
doi = "10.1016/j.jconrel.2018.01.015",
language = "English",
volume = "273",
pages = "13--20",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies

AU - Bown, Hanne Kinnunen

AU - Bonn, Catherine

AU - Yohe, Stefan T.

AU - Yadav, Daniela Bumbaca

AU - Patapoff, Thomas W.

AU - Daugherty, Ann L.

AU - Mrsny, Randall J.

PY - 2018/3/10

Y1 - 2018/3/10

N2 - Monoclonal antibodies (mAbs), which are now more frequently administered by subcutaneous (SC) injection rather than intravenously, have become a tremendously successful drug format across a wide range of therapeutic areas. Preclinical evaluations of mAbs to be administered by SC injection are typically performed in species such as mice, rats, minipigs, and cynomolgus monkeys to obtain critical information regarding formulation performance and prediction of PK/PD outcomes needed to select clinical doses for first-in-human studies. Despite extensive efforts, no preclinical model has been identified to date that accurately predicts clinical outcomes for these SC injections. We have addressed this deficiency with a novel in vitro instrument, termed Scissor, to model events occurring at the SC injection site and now further validated this approach using a set of eight mAbs for which clinical PK/PD outcomes have been obtained. Diffusion of these mAbs from the Scissor system injection cartridge into a large volume physiological buffer, used to emulate mAb movement from the SC injection site into the systemic circulation, provided distinct profiles when monitored over a 6 h period. Curve-fitting analysis of these profiles using the Hill equation identified parameters that were used, along with physicochemical properties for each mAb, in a partial least squares analysis to define a relationship between molecule and formulation properties with clinical PK outcomes. The results demonstrate that parameters of protein charge at neutral pH and isoelectric point (pI) along with combined formulation properties such as viscosity and mAb concentration can dictate the movement of the mAb from the injection cartridge to infinite sink compartment. Examination of profile characteristics of this movement provided a strong predictive correlation for these eight mAbs. Together, this approach demonstrates the feasibility of this in vitro modelling strategy as a tool to identify drug and formulation properties that can define the performance of SC injected medicines and provide the potential for predicting clinical outcomes that could be useful for formulation selection and a first-in-human clinical dosing strategy.

AB - Monoclonal antibodies (mAbs), which are now more frequently administered by subcutaneous (SC) injection rather than intravenously, have become a tremendously successful drug format across a wide range of therapeutic areas. Preclinical evaluations of mAbs to be administered by SC injection are typically performed in species such as mice, rats, minipigs, and cynomolgus monkeys to obtain critical information regarding formulation performance and prediction of PK/PD outcomes needed to select clinical doses for first-in-human studies. Despite extensive efforts, no preclinical model has been identified to date that accurately predicts clinical outcomes for these SC injections. We have addressed this deficiency with a novel in vitro instrument, termed Scissor, to model events occurring at the SC injection site and now further validated this approach using a set of eight mAbs for which clinical PK/PD outcomes have been obtained. Diffusion of these mAbs from the Scissor system injection cartridge into a large volume physiological buffer, used to emulate mAb movement from the SC injection site into the systemic circulation, provided distinct profiles when monitored over a 6 h period. Curve-fitting analysis of these profiles using the Hill equation identified parameters that were used, along with physicochemical properties for each mAb, in a partial least squares analysis to define a relationship between molecule and formulation properties with clinical PK outcomes. The results demonstrate that parameters of protein charge at neutral pH and isoelectric point (pI) along with combined formulation properties such as viscosity and mAb concentration can dictate the movement of the mAb from the injection cartridge to infinite sink compartment. Examination of profile characteristics of this movement provided a strong predictive correlation for these eight mAbs. Together, this approach demonstrates the feasibility of this in vitro modelling strategy as a tool to identify drug and formulation properties that can define the performance of SC injected medicines and provide the potential for predicting clinical outcomes that could be useful for formulation selection and a first-in-human clinical dosing strategy.

KW - Formulation design

KW - Monoclonal antibody

KW - Subcutaneous injection

KW - in vitro model

UR - http://www.scopus.com/inward/record.url?scp=85041405561&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2018.01.015

DO - 10.1016/j.jconrel.2018.01.015

M3 - Article

VL - 273

SP - 13

EP - 20

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -